Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy
- 27 January 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 113 (3), 337-343
- https://doi.org/10.1007/s12185-021-03085-y
Abstract
B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic malignancy of B-type lymphoid precursor cells. Minimal/measurable residual disease (MRD) is an important prognostic factor for B-ALL relapse. Traditional flow cytometry detection mainly relies on CD19-based gating strategies. However, relapse of CD19-negative B-ALL frequently occurs in patients who receive cellular and targeted therapy. This review will summarize the technical aspects of standard MRD assessment in B-ALL by flow cytometry, and then discuss the challenges of MRD strategies to deal with the scenario of CD19 negative or dim B-ALL relapse.Keywords
This publication has 59 references indexed in Scilit:
- Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemiaBlood Cancer Journal, 2013
- Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotypingLeukemia, 2010
- Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic LeukemiaAmerican Journal of Clinical Pathology, 2009
- Overexpression of CD49f in precursor B‐cell acute lymphoblastic leukemia: Potential usefulness in minimal residual disease detectionCytometry Part B: Clinical Cytometry, 2008
- Analysis of clinical flow cytometric immunophenotyping data by clustering on statistical manifolds: Treating flow cytometry data as high‐dimensional objectsCytometry Part B: Clinical Cytometry, 2008
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008
- CD58 Expression Decreases as Nonmalignant B Cells Mature in Bone Marrow and Is Frequently Overexpressed in Adult and Pediatric Precursor B-Cell Acute Lymphoblastic LeukemiaAmerican Journal of Clinical Pathology, 2005
- BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainingsLeukemia, 2001
- Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALLLeukemia, 1999
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998